Reviewing BioSig Technologies (BSGM) and Its Competitors

BioSig Technologies (OTCMKTS: BSGM) is one of 46 public companies in the “Electromedical equipment” industry, but how does it weigh in compared to its peers? We will compare BioSig Technologies to related businesses based on the strength of its analyst recommendations, profitability, dividends, risk, institutional ownership, earnings and valuation.

Risk & Volatility

How to Become a New Pot Stock Millionaire

BioSig Technologies has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, BioSig Technologies’ peers have a beta of 1.57, indicating that their average share price is 57% more volatile than the S&P 500.


This table compares BioSig Technologies and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioSig Technologies N/A N/A -1,090.30%
BioSig Technologies Competitors -136.44% 32.35% -12.78%

Earnings and Valuation

This table compares BioSig Technologies and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioSig Technologies N/A -$12.69 million -2.93
BioSig Technologies Competitors $1.10 billion $121.87 million -38.39

BioSig Technologies’ peers have higher revenue and earnings than BioSig Technologies. BioSig Technologies is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current recommendations and price targets for BioSig Technologies and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioSig Technologies 0 0 1 0 3.00
BioSig Technologies Competitors 146 439 968 26 2.55

As a group, “Electromedical equipment” companies have a potential upside of 17.77%. Given BioSig Technologies’ peers higher possible upside, analysts plainly believe BioSig Technologies has less favorable growth aspects than its peers.

Institutional and Insider Ownership

0.1% of BioSig Technologies shares are owned by institutional investors. Comparatively, 40.7% of shares of all “Electromedical equipment” companies are owned by institutional investors. 44.9% of BioSig Technologies shares are owned by company insiders. Comparatively, 20.2% of shares of all “Electromedical equipment” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


BioSig Technologies peers beat BioSig Technologies on 8 of the 12 factors compared.

About BioSig Technologies

BioSig Technologies, Inc., a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company was founded in 2009 and is headquartered in Los Angeles, California.

Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with's FREE daily email newsletter.

Leave a Reply